Related references
Note: Only part of the references are listed.A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors
Francesco Sbrana et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
Gianluca Trifiro et al.
DRUG SAFETY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy et al.
CIRCULATION (2019)
Application of PCSK9 Inhibitors in Practice Part 2: The Patient Experience
Tina M. Kaufman et al.
CIRCULATION RESEARCH (2019)
Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom
Ming-Hui Tai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia
Dean G. Karalis et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
PCSK9 inhibitors in clinical practice: Delivering on the promise?
Robert M. Stoekenbroek et al.
ATHEROSCLEROSIS (2018)
Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors
Omar Razek et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic
Barak Zafrir et al.
CARDIOVASCULAR THERAPEUTICS (2018)
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol 190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry
Salim S. Virani et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)
Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation
Giovanni Corrao et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Personalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs
Tiziana Sampietro et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol 190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry
Salim S. Virani et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)
Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors
Pallavi B. Rane et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Dionne M. Hines et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory
Aldo P. Maggioni et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
PCSK9 Inhibitors Economics and Policy
Mark A. Hlatky et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials
Aris Karatasakis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
Kathleen A. Fairman et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Amand F. Schmidt et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Factors affecting the uptake of new medicines: a systematic literature review
Agnes Lubloy
BMC HEALTH SERVICES RESEARCH (2014)
FROM THE ANALYST'S COUCH The dyslipidaemia market
Victoria Hudson
NATURE REVIEWS DRUG DISCOVERY (2014)
Share Paper
